Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
GlaxoSmithKline |
---|---|
Information provided by: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT00411073 |
This is a study to assess the effects of darapladib on the cardiac conduction of the heart as compared to placebo and moxifloxacin. This a four period crossover design with each period lasting about 10 days. There will be a 7 to 10 day wash out in between each period.
Condition | Intervention | Phase |
---|---|---|
Atherosclerosis |
Drug: Darapladib |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Crossover Assignment, Pharmacodynamics Study |
Official Title: | A Study to Evaluate the Effect of Repeat Oral Doses of Darapladib on Cardiac Conduction as Compared to Placebo and a Single Oral Dose of Moxifloxacin |
Estimated Enrollment: | 72 |
Study Start Date: | December 2006 |
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | GSK ( Study Director ) |
Study ID Numbers: | SB 480848/035 |
Study First Received: | December 12, 2006 |
Last Updated: | October 9, 2008 |
ClinicalTrials.gov Identifier: | NCT00411073 |
Health Authority: | United States: Food and Drug Administration |
QT study darapladib moxifloxacin |
Arterial Occlusive Diseases Atherosclerosis Moxifloxacin Vascular Diseases Arteriosclerosis |
Anti-Infective Agents Therapeutic Uses Cardiovascular Diseases Pharmacologic Actions |